# Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

> **NCT05728944** · PHASE3 · COMPLETED · sponsor: **LENZ Therapeutics, Inc** · enrollment: 229 (actual)

## Conditions studied

- Presbyopia
- Near Vision
- Refractive Error
- Eye Diseases

## Interventions

- **DRUG:** Aceclidine+Brimonidine combination ophthalmic solution
- **DRUG:** Aceclidine ophthalmic solution
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT05728944
- **Lead sponsor:** LENZ Therapeutics, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-06
- **Primary completion:** 2023-12-14
- **Final completion:** 2024-01-24
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728944, "Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05728944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*